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Background: Enhancer of zeste homolog 2 (EZH2) is a key epigenetic regulator in cancer cell survival, epithelial-
mesenchymal transition, and tumorigenesis. Inhibition of EZH2 has become a promising therapeutic option for
various human malignancies. Previously, we demonstrated that the EZH2/miR-30d/karyopherin (importin) beta 1
(KPNB1) signaling pathway is critical for malignant peripheral nerve sheath tumor (MPNST) cell survival in vitro and
for tumorigenesis in vivo. Here, we sought to determine the antitumor effects of pharmacological inhibition of
EZH2 on MPNST in vitro and in vivo.
Methods: We investigated the effects of an EZH2 inhibitor, 3-deazaneplanocin A (DZNep), on MPNST cell cycle,
survival and apoptosis in vitro and on MPNST xenograft tumor growth in vivo.
Results: We found that DZNep treatment impaired MPNST cell viability and proliferation by inducing apoptosis and
cell cycle arrest in vitro. Consistently, DZNep treatment also reduced EZH2 and KPNB1 protein levels and upregulated
miR-30d expression in MPNST cells. Intraperitoneal administration of DZNep significantly suppressed MPNST tumor
initiation and growth rates in a MPNST xenograft mouse model. Immunoblot and immunohistochemical analyses
showed that DZNep downregulated EZH2/KPNB1 signaling in vivo, thereby inhibiting MPNST tumor cell proliferation,
and induced cell death. We also found that EZH2 inhibited expression of another miR-30 family member, miR-30a, in
MPNST cells. Similar to miR-30d, miR-30a inhibited KPNB1 by targeting the KPNB1 3’ untranslated region in MPNST cells.
Our data also showed that EZH2 suppressed miR-200b expression and induced epithelial-mesenchymal transition in
MPNST cells.
Conclusion: These findings demonstrated that DZNep, an inhibitor of S-adenosyl-methionine–dependent
methyltransferase, suppressed EZH2/miR-30a,d/KPNB1 signaling and blocked MPNST tumor cell growth and
survival in vitro and in vivo. More importantly, our study indicated that pharmacological interference of EZH2 is a
potential therapeutic approach for MPNST.
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Malignant peripheral nerve sheath tumor (MPNST) is a
spindle-cell malignancy that arises from peripheral
nerves or deep neurofibromas [1]. MPNST behaves ag-
gressively, has a high rate of local recurrence, and readily
metastasizes to other organs. Because of its invasiveness,* Correspondence: pinzhang@mdanderson.org
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unless otherwise stated.metastasis, and resistance to chemotherapy and radio-
therapy, MPNST has a poor prognosis. Surgery and
chemotherapy are the main treatments for MPNST; no
targeted therapy for MPNST is available. Even with ag-
gressive surgery and chemotherapy, MPNST patients
have a 5-year survival rate of just 35%–50% [1], which
indicates an urgent need for novel therapies. The use of
RAS inhibitors to treat patients with plexiformThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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has been investigated in clinical trials. In one phase 2
trial, tipifarnib, a farnesyl transferase inhibitor that
blocks RAS’s ability to induce tumorigenesis, was found
to be an ineffective therapy for plexiform neurofibroma,
probably because RAS was activated through an alterna-
tive pathway. Therefore, novel therapeutic approaches
for MPNST are urgently needed.
Enhancer of zeste homolog 2 (EZH2), a histone-lysine
N-methyltransferase and a polycomb group protein, is a
critical component of polycomb repressive complex 2
(PRC2), a multimeric protein complex that also includes
EED, SUZ12, and RbAP46/48 [2]. PRC2 plays an essen-
tial role in the epigenetic maintenance of the repressive
H3K27me3 chromatin mark [3]. Abnormal EZH2 ex-
pression has been associated with various human malignan-
cies, including lymphoma and lung, breast, and prostate
cancers [3]. In glioblastoma multiforme, EZH2 has been
shown to be a functional oncogene, a prognostic factor, and
a potential therapeutic target [4]. However, the role of
EZH2 in MPNST pathogenesis is poorly understood. Our
recent research shows that EZH2 expression is significantly
higher in MPNST than in neurofibromas and normal nerve
tissues. EZH2 knockdown by RNA interference in MPNST
cell lines induces MPNST cell apoptosis in vitro and in-
hibits MPNST tumor growth in vivo, suggesting that EZH2
is a potential therapeutic target in MPNST [5].
Given the importance of EZH2 in human malignancies,
multiple groups have developed pharmacological inhibi-
tors of EZH2. One such inhibitor, 3-deazaneplanocin A
(DZNep), depletes cellular EZH2 protein and is considered
to be an inhibitor of S-adenosyl-methionine–dependent
methyltransferase [6,7]. Studies have shown that DZNep
treatment has antitumor effects in several cancer models,
such as prostate cancer, leukemia, and hepatocellular car-
cinoma [8-10]. These data demonstrate that the pharma-
cological inhibition of EZH2 activity is a promising
treatment for EZH2-driven cancers.
To investigate the effect of EZH2 inhibitor DZNep on
MPNST cell growth and survival in vitro, we performed
cell cycle, apoptosis, and viability analyses of MPNST cells
treated with DZNep. To assess the effect of DZNep on
tumor growth in vivo, we conducted tumor incidence and
growth analyses with use of an MPNST724 xenograft
mouse model. In this report, we showed that DZNep
inhibited MPNST cell viability by inducing cell cycle arrest
and apoptosis in vitro. Our results showed that DZNep
also inhibited MPNST724 xenograft tumor incidence and
growth rates in vivo. We found that DZNep depletes
EZH2, subsequently induces miR-30d and miR-30a ex-
pression that inhibit Karyopherin β1 (KPNB1) in MPNST
cells. In addition, we demonstrated that EZH2 transcrip-
tionally inhibits miR-200b expression and induces
epithelial-mesenchymal transition in MPNST cells.Materials and methods
Cell lines and immunohistochemical and western
blot analyses
Human NF1-related MPNST cell lines ST88-14, T265,
MPNST642, and S462 and non-NF1-related sporadic
human MPNST cell lines STS26T and MPNST724 were
maintained as previously described [5]. Primary cultured
normal human Schwann cells, purchased from ScienCell
Research Laboratories, served as controls. Authentica-
tion of cell lines was performed by short-tandem-repeat
DNA fingerprinting.
Immunohistochemical and Western blot analyses
were performed according to standard protocols with
minor modifications due to antibody optimization [11].
Commercially available antibodies were used for all
immunoblot and immunohistochemical detection of
EZH2 (1:1000, D2C9, Cell Signaling), KPNB1 (1:5000,
NB100-81650, Novus Biologicals,), cleaved PARP
(1:1000, ab32064, Abcam), vimentin (1:2000, RV202,
Santa Cruz), E-cadherin (1:1000, H-108, Santa Cruz),
Ki-67 (1:1000, MIB-1; Dako), cleaved caspase 3
(1:1000, BioCare Medical), GAPDH-HRP (1:5000,
ab9483, Abcam), and actin-HRP (1:5000, I-19, Santa
Cruz). Secondary antibodies were horseradish peroxid-
ase (HRP)–conjugated rabbit anti-mouse (1:5000,
Santa Cruz) and goat anti-rabbit (1:3000, Santa Cruz)
antibodies for Western blot and immunohistochemical
analyses.EZH2 inhibitor treatment, PCR analyses, cell viability
assay, cell cycle analyses, and apoptosis analyses
The EZH2 inhibitor DZNep (Cayman Chemical) was
dissolved in DMSO to yield the appropriate stock con-
centrations and then frozen at −80°C until further use.
Cells were exposed to DZNep for 72 hours and then
harvested for qRT-PCR as well as Western blot, cell via-
bility, and apoptosis analyses. For qRT-PCR analyses of
miRNAs, total RNA was isolated by using TRIZOL (Life
Technologies) and reverse transcribed to cDNA by
using the RT2 miRNA First Strand kit (QIAGEN). Next,
q-PCR was performed with miR-200b, miR-30d, and
miR-30a specific primers (QIAGEN). SNORD47 was
used as a normalizing control for miRNA qRT-PCR
analyses. In vitro cell viability was measured by using a
CellTiter96 Aqueous Non-Radioactive Cell Proliferation
Assay kit (Promega) according to its standard protocol.
For the cell apoptosis assays, cells were stained with
annexin V and propidium iodide (PI) according to the
manufacturer’s protocol for an apoptosis detection kit
(BD Pharmingen). For cell cycle analyses, cells were
fixed and stained with PI for 30 minutes and then ana-
lyzed in a FACSCalibur flow cytometer (BD Biosci-
ences). Data were analyzed with Cell Quest software.
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All animal procedures and care were approved by MD
Anderson’s Institutional Animal Care and Use Committee.
The MPNST xenograft mouse model using MPNST724
cells has been described previously [12]. For this experi-
ment, 2 × 106 MPNST724 cells were suspended in 100 μl
PBS and then injected subcutaneously into the flanks of 6-
week-old female hairless SCID mice. Three weeks after in-
jection, mice were randomized into three groups (n = 9/
group) to receive intraperitoneal injections of 100 μl of ve-
hicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep twice per
week (Monday and Thursday) every other week. Mice were
weighed, and the dimensions of their tumors were mea-
sured with calipers twice weekly. Tumor volumes were cal-
culated by using the following equation: (length/2) ×
(width)2. Mice were monitored until their tumors were
1.5 cm in diameter or their morbidity necessitated euthan-
asia. Mice were killed humanely by CO2 inhalation, and
their tumors were resected, weighed, fixed in formalin, and
paraffin-embedded for H&E and immunohistochemical
studies. Slides of formalin-fixed, paraffin-embedded tumor
tissues from the control untreated group and the two
EZH2 inhibitor–treated groups were prepared and sub-
jected to immunohistochemical staining for cleaved caspase
3 and Ki-67. Differences in xenograft growth in vivo were
assessed by using a two-tailed Student t test.
Promoter activity analyses
A miR-30d promoter construct was generated previously
[5]. Promoter regions of miR-200b were amplified by
genomic PCR with use of specific primers and cloned
into the pGL vector directionally at NheI and BglII sites
(Additional file 1: Table S1). For the promoter activity
assay, empty pGL vector, pGL-miR-200b promoter, or
pGL-miR-30d promoters were transfected into MPNST
cells using lipofectamine 2000 (Invitrogen) reagent. Cells
were then treated with vehicle only or DZNep. The pRL
vector was used as an internal control. After 48 hours,
cells were lysed and subjected to luciferase assays by
using a dual luciferase assay kit (Promega) according to
the manufacturer’s instructions.
miRNA overexpression and reporter activity assays
To overexpress miR-30a in MPNST cells, negative con-
trol miRNA and miR-30a mimics (Dharmacon) were
transfected into MPNST cells by using lipofectamine
2000. After 48 hours, cells were harvested for Western
blot analyses. miR-30d and miR-200b target sequence
reporters were constructed by cloning 3 repeats of miR-
30d and miR-200b perfect binding sequences into the 3’
end of the luciferase gene of an empty pLightSwitch vec-
tor (SwitchGear Genomics) using XbaI and XhoI sites
(Additional file 1: Table S1). The wild-type and mutant
KPNB1 3’UTR reporter was generated previously [5].For luciferase reporter analyses, luciferase reporters
were transfected into MPNST cells with lipofectamine
2000. After 48 hours, reporter activity was assessed with
use of LightSwitch luciferase assay reagents (Switch-
Gear Genomics).
Statistical analyses
Data were analyzed by means of a two-sided unpaired t
test using GraphPad software (Prism 6.0) and were shown
as the mean ± SD of multiple independent experiments. A
p value of <0.05 was considered statistically significant.
Results
Pharmacological inhibition of EZH2 with DZNep inhibits
MPNST cell growth and induces apoptosis in vitro
Because of the importance of EZH2-regulated miR-30d
expression that modulates KPNB1 in MPNST cell survival
and apoptosis in vitro and in vivo [5], pharmacological in-
hibition of EZH2 represents a promising therapeutic ap-
proach for this tumor type. Therefore, we hypothesized
that EZH2 inhibitor DZNep treatment would suppress
MPNSTcell proliferation and induce cell death of MPNST
cells in vitro. To test this hypothesis, we subjected S462
and MPNST724 cells to increasing concentrations of
DZNep (0, 0.5, 1, 2, 5, and 10 μM) for 72 hours and mea-
sured cell apoptosis and viability. Flow cytometry analyses
of S462 and MPNST724 cells stained with annexin V and
PI identified two apoptotic cell populations: early apop-
totic cells (annexin V+/PI-) and late apoptotic cells
(annexin V+/PI+) (Figure 1A and B). Results showed that
total apoptotic cells (annexin V+), including early apop-
totic cells and late apoptotic cells, increased significantly,
from 0.7% to 31% for S462 cells (Figure 1A) and from 8%
to 27% for MPNST724 cells (Figure 1B). In response to
treatment with various doses of DZNep, the apoptotic cell
populations for S462 cells increased 3 to 7 times their no-
treatment control size (3% to 21% on average); the apop-
totic cell populations for MPNST724 cells increased 1.5 to
2.5 times their no-treatment control size (8% to 20% on
average) (Figure 1C). We then determined whether
DZNep also reduced cell viability, as measured by the
MTT assay (Figure 1D). Results showed that DZNep sig-
nificantly reduced viability of S462 cells (from 100% to
30% on average) and MPNST724 cells (from 100% to 50%
on average). We also assessed whether MPNST724 and
S462 cell cycle profiles were changed by DZNep treat-
ment. Flow cytometry cell cycle analyses with PI staining
showed that for S462 cells, DZNep treatment increased
the percentage of G2 phase cells and decreased the per-
centage of S phase cells (Additional file 2: Figure S1). For
MPNST724 cells, DZNep treatment increased the per-
centage of G1 phase cells and decreased the percentage of
S phase cells (Additional file 2: Figure S2). These data
demonstrated that DZNep treatment induced cell cycle
AB
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Figure 1 Pharmacological inhibition of EZH2 by DZNep induced MPNST cell apoptosis. (A and B) Annexin V/PI flow cytometry analyses of
S462 (A) and MPNST724 (B) cells treated with DZNep at various concentrations. (C and D) Apoptosis (C) and cell viability (D) assays for S462 and
MPNST724 cells treated with DZNep for 72 hours. Mean ± SD values are shown (n = 3); *p < 0.05 compared with control, Student t test.
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and diminishing survival in MPNST cells in vitro.
On the basis of our previous study showing that EZH2
inhibits miR-30d and that miR-30d suppresses KPNB1 [5],
we postulated that the EZH2 inhibitor DZNep would re-
store miR-30d expression with subsequent inhibition of
KPNB1 expression. Under the same experimental condi-
tions, immunoblotting revealed that EZH2 and KPNB1
expression decreased in S462 and MPNST724 cells that
were treated with DZNep for 72 hours (Figure 2A). Not
surprisingly, DZNep treatment increased the apoptosis
marker PARP cleavage (Figure 2A). These data showed
that DZNep inhibited EZH2/KPNB1 signaling in MPNST
cells in vitro.To determine whether EZH2 depletion by DZNep treat-
ment also affects miR-30d expression in MPNST cells, we
performed qRT-PCR analyses. Results showed that DZNep
treatment restored the expression of miR-30d (Figure 2B).
In our previous study, we showed that EZH2 inhibited
miR-30d promoter activity in MPNST cells [5]. Here, we
tested the effects of DZNep on miR-30d promoter activity
in MPNST cells. We found that DZNep treatment also in-
creased the promoter activities of miR-30d in S462 cells
(Figure 2C). More importantly, we used the standard miR-
30d targeting reporter construct to determine whether
DZNep treatment induced functional miR-30d expression
in MPNST cells. Data showed that DZNep treatment sig-




Figure 2 DZNep inhibited EZH2/miR-30d/KPNB1 signaling in MPNST cells. (A) Western blot analyses of EZH2, cleaved PARP (cPARP), KPNB1,
and GAPDH (loading control) in MPNST724 and S462 cells treated with DZNep at increasing concentrations for 48 hours. (B) qRT-PCR analyses of
miR-30d expression in MPNST724 and S462 cells treated with DZNep for 96 hours. miR-30d expression was normalized to SNORD47. Mean ± SD
values are shown (n = 3); *p < 0.05, Student t test. (C) Promoter activity assay showed that DZNep treatment increased miR-30d promoter activity
in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05; Student t test. (D) Luciferase reporter assay showed that DZNep treatment inhibited
miR-30d target reporter activity in S462 cells. Mean ± SD values are shown (n = 3); **p < 0.01, Student t test. (E) Luciferase reporter assay indicated
that DZNep treatment inhibited wild-type (WT) KPNB1 3’UTR reporter activity but not mutant (MT) KPNB1 3’UTR reporter activity in S462 cells.
Mean ± SD values are shown (n = 3); *p < 0.05, Student t test.
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duced MPNST cells apoptosis by depleting EZH2 protein
and enhancing the expression and activity of miR-30d in
MPNST cells.
To further confirm that DZNep-dependent KNPB1 in-
hibition occurs through miR-30d activation, we transfected
wild-type or mutant KPNB1 3’UTR reporter constructsinto S462 cells and then treated the cells with either vehicle
control or DZNep. Results showed that DZNep signifi-
cantly reduced the activity of the wild-type KPNB1 3’UTR
reporter construct but did not affect activity levels of the
mutant KPNB1 3’UTR reporter (Figure 2E). Together, these
data demonstrated that DZNep depletes EZH2 expression,
resulting in increased miR-30d expression and activity,
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These findings underscore the importance of this signaling
axis in MPNSTcell growth and survival.
DZNep inhibits MPNST tumorigenesis and growth in vivo
To evaluate the effects of pharmacological inhibition of
EZH2 in vivo, we next tested whether DZNep treatment
blocked MPNST tumor initiation and growth in an
MPNST724 xenograft mouse model. After the subcuta-
neous implantation of 2 × 106 MPNST724 cells, mice
were treated with vehicle control only, 1 mg/kg DZNep,
or 5 mg/kg DZNep intraperitoneally twice per week
every other week. The doses of DZNep were chosen
based on previous studies that had determined doses
that are safe for mice and effective for EZH2 inhibition
in vivo [10,13]. DZNep treatment started at the third
week after cell implantation and continued for 6 weeks.
The whole animal study was stopped at 13 weeks after
tumor cell inoculation. Results showed that MPNST
tumor initiation and growth rates were markedly sup-
pressed by DZNep treatment. At 1 mg/kg and 5 mg/kg,
DZNep decreased tumor incidence from 78% (vehicle-
control group) to 44% (Figure 3A and B). The tumor
volumes of the 1 mg/kg DZNep group (300 mm3) also
significantly differed from those of the control group
(700 mm3) (Figure 3B). In addition, tumor volumes in
the 5 mg/kg group (100 mm3) were significantly reduced
compared with those of the 1 mg/kg group (300 mm3)
(Figure 3B).
To confirm the depletion of EZH2 in MPNST xeno-
graft tumors by DZNep treatment in vivo, we conducted
Western blot analyses of EZH2 and KPNB1 protein ex-
pression in two xenograft tumor samples randomly se-
lected from each group. Data showed that DZNep
decreased the EZH2 and KPNB1 protein levels of tumor
samples (Figure 3C). Together, these results suggested
that DZNep inhibited the EZH2/KPNB1 signaling path-
way and MPNST xenograft tumor growth in mice.
Next, to determine the effects of DZNep on MPNST cell
proliferation and apoptosis in vivo, immunohistochemical
analyses of cleaved caspase 3 (apoptosis marker) and Ki-
67 (cell proliferation marker) were performed. Results
showed that DZNep treatment increased cleaved caspase
3 signals and decreased Ki-67 signals of xenograft tumors
in a dose-dependent manner (Figure 4), suggesting that
DZNep treatment induced MPNST cell apoptosis and
inhibited MPNSTcell proliferation in vivo.
EZH2-regulated miR-30a targets KPNB1 in MPNST cells
In our previous study, we performed miRNA microarray
analyses to identify miRNAs differentially expressed in
EZH2-knockdown MPNST cells [5]. These microarray
studies revealed that, in addition to miR-30d, another
miR-30 family member, miR-30a, was also upregulatedin EZH2-knockdown cells compared with negative controls
in MPNST724, S462, and STS26T cells [5]. Because miR-
30a shares the same “seed sequence” with other miR-30
family miRNAs for targeting mRNA (Figure 5A), we hy-
pothesized that EZH2 may also regulate miR-30a and that
miR-30a may inhibit KPNB1 in MPNST cells. To confirm
our finding in a microarray, we conducted qRT-PCR ana-
lyses for miR-30a in an independent EZH2-knockdown ex-
periment in MPNST724 and S462 cells. Our data showed
that the miR-30a level significantly increased in EZH2-
knockdown cells compared with the level in control cells
(Figure 5B). Quantitative RT-PCR analyses also showed that
miR-30a expression was significantly enhanced in DZNep-
treated S462 and MPNST724 cells (Figure 5C).
To confirm whether miR-30a inhibits KPNB1 in
MPNST cells, we transfected miR-30a mimics into
MPNST724 and S462 cells. Western blot analyses indi-
cated that the KPNB1 protein level was decreased by miR-
30a mimics in both cell lines (Figure 5D). To determine
whether miR-30a directly targets KPNB1 mRNA, we used
a KPNB1 3’UTR reporter construct. A reporter activity
assay showed that the miR-30a mimic specifically inhib-
ited activity of the wild-type KPNB1 3’UTR reporter but
not activity of a KPNB1 3’UTR reporter in which the miR-
30a targeting sequence was mutated (Figure 5E). This re-
sult suggested that miR-30a directly suppresses KPNB1 by
targeting the KPNB1 mRNA 3’UTR region.
To determine the expression of miR-30a in other
MPNST cell lines, we performed qRT-PCR of miR-30a
in a larger panel of MPNST cell lines (MPNST724, S462,
STS26T, MPNST624, T265, and ST14). Results showed
that miR-30a was decreased in MPNST cells compared
with levels in normal Schwann cells (Figure 5 F). The ex-
pression of miR-30a had an inverse correlation with
EZH2 protein and KPNB1 protein in multiple human
normal Schwann cells and in the same panel of MPNST
cell lines (5). These results suggested that EZH2/miR-
30a/KPNB1 signaling may be common in MPNST cells.
EZH2 regulates miR-200b expression in MPNST cells
Our previous miRNA microarray analyses also showed
that miR-200b was upregulated when EZH2 was
knocked down in MPNST724, S462, and STS26T cells
[5]. We here confirmed the miR-200b expression results
by qRT-PCR analyses. In an independent experiment,
miR-200b expression increased significantly in EZH2-
knockdown cells compared with non-targeting siRNA con-
trol cells in the MPNST724, S462, and STS26T cell lines
(Figure 6A). We also determined whether the miR-200b
level is increased as EZH2 is inhibited by DZNep treatment.
Quantitative RT-PCR analyses showed that miR-200b ex-
pression was significantly increased by DZNep treatment in




Figure 3 DZNep suppressed MPNST724 xenograft tumor initiation and growth in vivo. (A) MPNST724 xenograft tumor groups treated with
vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep 13 weeks after subcutaneous injection (n = 9 mice per group). (B) Growth curves of tumors
treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep over a period of 13 weeks. Mean ± SD values are shown; *p < 0.05, Student t test.
(C) Western blot analyses of EZH2, KPNB1, and actin in tumor MPNST samples treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep.
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miR-200b, the promoter region of miR-200b was ampli-
fied from genomic DNA of MPNST cells by PCR and
cloned into a pGL vector [14]. To determine whether
EZH2 could inhibit miR-200b expression at the pro-
moter level, we co-transfected non-targeting control
siRNA or EZH2 siRNA with miR-200b promoter con-
structs into MPNST724 and S462 cells. The pRL con-
struct was used as an internal control. Promoter activitywas measured at 48 hours after transfection. Results
showed that EZH2 knockdown significantly increased
miR-200b promoter activity in both cell lines, suggesting
that EZH2 suppresses miR-200b expression at the tran-
scription level (Figure 6C).
We further investigated whether EZH2 knockdown in-
duced functional miR-200b expression through the use
of miR-200b target reporter systems. Based on miR-200b
sequences, three repeats of miR-200b perfect match
Figure 4 Immunohistochemical analyses of MPNST tumors treated with control or DZNep regeant. Represented images of H&E staining
and immunohistochemical analyses of cell apoptosis marker cleaved caspase 3 and cell proliferation marker Ki-67 in MPNST724 xenograft tumor
samples treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep. (×200 magnification).
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pLightSwitch reporter vector. Therefore, these reporter
constructs served as functional targets for miR-200b in
transfected cells. We co-transfected control or EZH2
siRNA with miR-200b target reporter into MPNST724
and S462 cells. Luciferase activity assays showed that by
silencing EZH2, miR-200b target reporter activity was
significantly reduced (Figure 6D). This suggested that
EZH2 knockdown induced functional miR-200b in
MPNST cells.
In addition to EZH2 knockdown, we also tested the
effects of EZH2 inhibitor DZNep treatment on miR-
200b promoter activity and miR-200b target reporter
activity in MPNST cells. Results showed that DZNep
treatment significantly induced miR-200b promoter ac-
tivity in S462 cells (Figure 6E). However, miR-200b tar-
get reporter activity was significantly inhibited by
DZNep treatment in S462 cells (Figure 6 F). These re-
sults indicated that EZH2 suppressed miR-200b tran-
scription in MPNST cells.
It has been shown that miR-200b reduced epithelial–
mesenchymal transition by modulating vimentin and
E-cadherin expression [15,16]. Therefore, we deter-
mined whether miR-200b upregulation by EZH2
siRNA had similar effects in MPNST cells. Western
blot analyses showed that transient silencing of EZH2
resulted in increased E-cadherin and decreased vimen-
tin expression in MPNST724, S462, and STS26T cells
(Figure 6G). These results suggested that EZH2 knock-
down may cause mesenchymal–epithelial transition in
MPNST cells.Discussion
In this study, we found that pharmacological inhibition
of EZH2 by DZNep depleted EZH2 expression, induced
expression of miR-30a and miR-30d, and inhibited
KPNB1 expression in MPNST cells. By impairing the
EZH2/miR-30a,d/KPNB1 pathway, DNZep induced
MPNST cell apoptosis and cell cycle arrest, which to-
gether decreased MPNST cell viability and suppressed
cell survival in vitro. We also observed a consistent cor-
relation between EZH2, miR-30a/d, and KPNB levels
and MPNST cell phenotypes (apoptosis, cell cycle arrest,
viability in vitro and tumorigenicity in vivo) at various
concentrations of DZNep (from 0 to 10 μM). These re-
sults suggested that these phenotypes of MPNST cells
induced by DZNep were mediated by EZH2/miR-30a,d/
KPNB1 inhibition.
We also demonstrated that DZNep treatment inhib-
ited MPNST tumor initiation and growth rates in a
mouse xenograft model. The DZNep doses that we se-
lected have been proven to be effective in EZH2 inhib-
ition and safe for animals [10,13]. At high concentration
of DZNep (5 mg/kg), MPNST tumors shrunk more
profoundly than did tumors treated with low-dose
DZNep (1 mg/kg). However, the tumors of both treat-
ment groups did not disappear completely. These find-
ings suggested that a higher DZNep dose may be needed
for optional antitumor effects in MPNST. However, the
high cost of DZNep limited our ability to perform further
experiments. Nevertheless, our results suggested that







Figure 5 EZH2-regulated miR-30a targeted KPNB1 in MPNST cells. (A) Putative miR-30a and miR-30d target site in the wild-type KPNB1 3’UTR
region. (B) qRT-PCR analyses of miR-30a in MPNST724 and S462 cells transfected with a negative control or EZH2 siRNA. miR-30a expression was
normalized to SNORD47. Data are shown as mean ± SD (n = 3); *p < 0.05, Student t test. (C) qRT-PCR analyses of miR-30a in S462 and MPNST724 cells
treated with DZNep for 96 hours. miR-30d expression was normalized to SNORD47. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (D)
Western blot analyses of KPNB1 and actin in S462 and MPNST724 cells transfected with a negative control (Ctl) or miR-30a (30a) mimics. (E) Luciferase
reporter assay showed that miR-30a inhibited wild-type (WT) KPNB1 3’UTR reporter activity but not mutant (MT) KPNB1 3’UTR reporter activity in S462
cells. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (F) qRT-PCR analyses of miR-30a expression in normal Schwann cells (NSC) and
multiple MPNST cell lines (MPNST724, S462, STS26T, MPNST624, T265, and ST88-14).
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adenosyl-L homocysteine hydrolase, which is required
for EZH2-dependent methylation [3]. It has been shown
that DZNep depletes cellular EZH2 levels and selectively
blocks the trimethylation of H3K27 [9,16]. DZNep dem-
onstrates antitumor activities against breast, lung, brain,
prostate, and liver cancer cells in vitro [3]. More import-
antly, the in vivo efficacy of DZNep has been reported in
a murine leukemia model and in a hepatocellular cancer
model [10,13]. In addition, DZNep has blocked cancercell migration and invasion in prostate cancer cells and
has reduced tumor-associated blood vessel formation in
a glioblastoma xenograft model [17]. However, DZNep is
not considered a specific EZH2 inhibitor because it has
a general histone methyltransferase inhibitory effect [7].
Several recently developed novel EZH2 small-molecule
inhibitors (GSK126, EPZ-6438, and EI1) have shown po-
tent, highly selective, and S-adenosyl-L homocysteine
hydrolase competitive inhibition of wild-type and mu-




Figure 6 EZH2 regulated miR-200b expression and mesenchymal-epithelial transition in MPNST cells. (A) qRT-PCR analyses of miR-200b
in MPNST724, S462, and STS26T cells transfected with a negative control or EZH2 siRNA. miR-200b expression was normalized to SNORD47. Data
are shown as mean ± SD (n = 3); *p < 0.05, Student t test. (B) qRT-PCR analyses of miR-200b in S462 and MPNST724 cells treated with DZNep for
72 hours. miR-200b expression was normalized to SNORD47. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (C) Promoter activity
assay showed that EZH2 knockdown increased miR-200b promoter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05, Student
t test. (D) Luciferase reporter assay showed that EZH2 knockdown inhibited miR-200b target reporter activity in S462 cells. Mean ± SD values are
shown (n = 3); *p < 0.05, Student t test. (E) Promoter activity assay showed that DZNep treatment induced miR-200b promoter activity in S462
cells. Mean ± SD values are shown (n = 3); *p < 0.05; Student t test. (F) Luciferase reporter assay showed that DZNep treatment suppressed
miR-200b target reporter activity in S462 cells. Mean ± SD values are shown (n = 3); **p < 0.01, Student t test. (G) Western blot analyses of EZH2,
vimentin, E-cadherin, and actin in MPNST724, S462, and STS26T cells transfected with a negative control or EZH2 siRNA.
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Zhang et al. Molecular Cancer  (2015) 14:55 Page 11 of 12H3K27me3 levels, and reactivate silenced PRC2 target
genes [18-20]. These compounds have been shown to
effectively inhibit the proliferation of multiple tumor
cell lines, induce apoptosis in vitro, and markedly in-
hibit the growth of diffuse large B-cell lymphoma and
pediatric malignant rhabdoid tumor xenografts in mice
[18-20]. Our future studies include examining whether
new EZH2 inhibitors will also have anti-MPNST effects
in vitro and in vivo by using the MPNST724 mouse
xenograft model.
EZH2 has been shown to be a critical regulator of
epithelial-mesenchymal transition, which is a critical step
for initiation of cancer invasion and metastasis [21]. EZH2
promotes EMT directly by inhibiting the expression of E-
cadherin and indirectly through the NF-κB/Twist pathway
[22,23]. Additionally, miR-200b is known to act as an in-
hibitor of EMT by targeting the transcription faction
ZEB1/2 and then by activating E-cadherin [15,16]. Our
study has shown that EZH2 directly inhibits miR-200b ex-
pression in MPNST, which may ultimately also contribute
to EMT progression, MPNST invasion and metastasis.
Interestingly, miR-30a/d have been shown to inhibit EMT
and promote mesenchymal-epithelial transition of human
pancreatic islet cells [24]. The miR-200 and miR-30 fam-
ilies have been shown to induce mesenchymal-epithelial
transition [25]. Another report showed that miR-30d tar-
gets EZH2 directly [26], indicating that EZH2 and miR-30d
inhibit each other and form a negative-feedback loop.
Together with our findings, these data suggest that EZH2-
regulated miR-200 and miR-30 family members may modu-
late cell survival and EMT in numerous different cancers.
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